GSK sells Nimenrix and Mencevax meningitis vaccines to Pfizer.

GlaxoSmithKline plc announced it is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc). The sale follows commitments given to the European Commission and other regulators in connection with the merger control clearances obtained for GSK�s three-part transaction with Novartis AG, which completed on 2 March 2015. As part of the transaction, GSK acquired Novartis�s vaccines business (excluding influenza vaccines) including the meningitis vaccines Menveo and Bexsero.

In order to satisfy regulatory clearances as part of the transaction, GSK agreed to divest its legacy meningitis vaccines Nimenrix and Mencevax, which are sold outside the US and achieved combined global sales in 2014 of �34 million.